Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Resolver, Bioperl 0.7

Premium

Rosetta Inpharmatics has launched version 2.0 of the Rosetta Resolver enterprise-wide expression data analysis system.

The new version is able to accept and analyze data from single-color, intensity-based DNA chip technologies as well as two-color, ratio-based chips. The system’s error models now compute quality statistics for each intensity measurement and produce P-values for each present/absent call.

Resolver 2.0 also includes a utility that enables automated, batch processing of Affymetrix GeneChip array data files. The system converts, imports, and exports data in the Gene Expression Markup Language (GEML) format.

Version 2.0 is available now through Rosetta’s strategic partner, Agilent Technologies.

The Bioperl 0.7 release is now available at www.bioperl.org.

The release brings a number of new features to bioperl, including an improved sequence feature model and added support in Genbank/ EMBL format parsing. There are also explicit gene, transcript, and exon SeqFeature objects to support CDS retrieval and exon shuffling, new modules for running Blast within perl, and modules for running multiple sequence alignment tools.

Filed under

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.